Mark Kowieski - 22 May 2024 Form 3 Insider Report for Evoke Pharma Inc (EVOK)

Role
Chief Financial Officer
Signature
/s/ Mark Kowieski
Issuer symbol
EVOK
Transactions as of
22 May 2024
Net transactions value
$0
Form type
3
Filing time
30 May 2024, 18:09:14 UTC
Next filing
08 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding EVOK Common Stock 5,000 22 May 2024 By IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EVOK Stock Option (Right to Buy) 22 May 2024 Common Stock 16,000 $2.09 Direct F1
holding EVOK Stock Option (Right to Buy) 22 May 2024 Common Stock 7,500 $4.01 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest at the rate of 1/48th of the original number of shares on each monthly anniversary of June 13, 2022, subject to the reporting person's continuous service to the issuer on each such vesting date.
F2 The option shall vest at the rate of 1/48th of the original number of shares on each monthly anniversary of January 1, 2023, subject to the reporting person's continuous service to the issuer on each such vesting date.